The genus Candida includes about 200 different species, but only a few species are human
opportunistic pathogens and cause infections when the host becomes debilitated or …

The magnitude of drug interactions between azole antifungals and immunosuppressants is
drug and patient specific and depends on the potency of the azole inhibitor involved, the …

An efficient microwave-assisted synthesis of new (Z)-5-arylidenerhodanines under solvent-
free conditions is described and their in vitro antifungal activity was evaluated following the …

Over the past several decades, there has been substantial progress in the management of
patients with febrile neutropenia. However, the ever‐changing patterns of infection, ecology …

Phytolaccoside B (1), an antifungal monodesmoside triterpenoid glycoside isolated from
berries of Phytolacca tetramera Hauman (Phytolaccaceae), alters the morphology of yeasts …

Concurrent or sequential antifungal treatment for invasive mycoses has been typically
considered as an option to improve results of monotherapy. However, data on the efficacy of …

We report on the synthesis, biological function, and a plausible mode of action of a new
group of lipopeptides with potent antifungal and antibacterial activities. These lipopeptides …

Abstract▴ Posaconazole is a triazole antifungal agent, administered as an oral suspension,
with an extended spectrum of in vitro activity.▴ Posaconazole 800 mg/day demonstrated …

Although many antifungal agents are available in clinical treatment, increasing resistance of
fungi, especially Candida species, to the available drugs requires the development of new …

Fungal infections with increasing resistance to conventional therapies are a growing
concern. Candida albicans is a major opportunistic yeast responsible for mucosal and …